Literature DB >> 9574114

[Guidelines in oncologic surgery--malignant thyroid tumors].

H D Röher1, D Simon, P E Goretzki.   

Abstract

Guidelines for a highly effective radical treatment protocol of thyroid cancer are based on its histopathological classification. The bases are total thyroidectomy, including the central lymph node compartment parathyroidal and paratracheal, extended to uni- or bilateral cervical lymph node dissection in case of clinical manifestation or very advanced tumor stage. Postoperative control or treatment by radioiodine is obligatory for all differentiated thyroid carcinoma. Reoperative surgery is useful for locoregional recurrence. Limited unilateral thyroid surgery is only justified in selected cases of primary tumors less than 1 cm diameter in a low-risk patient group.

Entities:  

Mesh:

Year:  1997        PMID: 9574114

Source DB:  PubMed          Journal:  Langenbecks Arch Chir Suppl Kongressbd        ISSN: 0942-2854


  5 in total

1.  Prognostic significance of disseminated tumor cells in the connective tissue of patients with medullary thyroid carcinoma.

Authors:  Oliver Gimm; Viola Heyn; Ulf Krause; Carsten Sekulla; Jörg Ukkat; Henning Dralle
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

Review 2.  Lateral and mediastinal lymph node dissection in differentiated thyroid carcinoma: indications, benefits, and risks.

Authors:  Yasuhiro Ito; Akira Miyauchi
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

Review 3.  Lateral lymph node dissection guided by preoperative and intraoperative findings in differentiated thyroid carcinoma.

Authors:  Yasuhiro Ito; Akira Miyauchi
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

4.  Classification of locoregional lymph nodes in medullary and papillary thyroid cancer.

Authors:  T J Musholt
Journal:  Langenbecks Arch Surg       Date:  2013-12-05       Impact factor: 3.445

5.  Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer.

Authors:  Andreas Machens; Steffen Hauptmann; Henning Dralle
Journal:  World J Surg       Date:  2007-10       Impact factor: 3.282

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.